Medically reviewed by Dr. Ploy, MD, Qualified Peptide Therapy Doctor, Board Certified in Family Medicine, Regenerative & Longevity Medicine Specialist , licensed by the Medical Council of Thailand.
Last reviewed: June 2026
Tesamorelin stands apart from every other peptide on this site for one reason: it is the only growth hormone releasing hormone (GHRH) analogue to have completed a phase 3 clinical trial programme and received regulatory approval from the US Food and Drug Administration. Under the brand name Egrifta, it was approved in November 2010 for a specific and well-defined indication. Understanding what that means, what the evidence actually shows, and how it compares to other GH-axis peptides helps patients and physicians make better-informed decisions.
The GHRH Mechanism: What Tesamorelin Actually Does
Tesamorelin is a synthetic analogue of endogenous growth hormone releasing hormone, the peptide produced by the hypothalamus that signals the pituitary gland to secrete growth hormone. By binding to and activating GHRH receptors in the anterior pituitary, Tesamorelin triggers pulsatile GH release, meaning GH is secreted in bursts rather than as a continuous elevation.
This is physiologically significant. The pituitary normally releases GH in pulses, particularly during sleep. Pulsatile secretion is how the body maintains downstream IGF-1 production, which mediates most of GH’s metabolic effects, while limiting the receptor desensitisation that occurs with sustained GH exposure. Tesamorelin preserves this pulse pattern rather than overriding it.
The downstream sequence is straightforward: Tesamorelin binds GHRH receptors, the pituitary secretes GH, GH stimulates IGF-1 production in the liver and peripheral tissues, and elevated IGF-1 drives lipolysis preferentially in visceral adipose tissue. The preferential effect on visceral fat (rather than subcutaneous fat) is explained by the higher density of GH receptors in visceral adipocytes: the same IGF-1 rise produces a proportionally larger lipolytic response in visceral fat.
FDA Approval: The Egrifta Story
The FDA approved Tesamorelin (Egrifta, Theratechnologies) in November 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The approval was based on two randomised, placebo-controlled, double-blind phase 3 trials, the results of which were published in the New England Journal of Medicine.
In those trials, Tesamorelin 2 mg daily reduced trunk fat by approximately 15 to 18 percent from baseline compared to placebo at 26 weeks, with visceral adipose tissue area measured by CT scan as the primary endpoint. The reduction was statistically significant, reproducible across both trials, and accompanied by improvements in lipid profiles, including reductions in triglycerides. This phase 3 programme is what no other GHRH analogue, including CJC-1295, has completed.
HIV-associated lipodystrophy is a specific metabolic complication of long-term antiretroviral therapy. It is characterised by excess visceral fat accumulation alongside peripheral fat loss, producing a pattern of central adiposity that does not respond adequately to lifestyle modification. Tesamorelin addresses the visceral component directly through the GH axis.
Clinical-grade. Doctor-prescribed. COA on every batch.
All protocols use pharmaceutical-standard peptides manufactured in Thailand's licensed compounding laboratories, with full cold-chain logistics.
Why Visceral Fat Is Metabolically Distinct
To understand why Tesamorelin’s selective visceral fat reduction matters, it helps to understand what makes visceral fat different from subcutaneous fat.
Visceral adipose tissue wraps around the abdominal organs and drains via the portal circulation directly into the liver. Free fatty acids and inflammatory cytokines released from visceral fat reach the liver before they reach peripheral circulation, which is why high visceral fat drives hepatic insulin resistance, elevates triglycerides, and increases cardiovascular risk independently of total body weight. An individual with significant visceral adiposity but a normal BMI carries a substantially higher cardiometabolic risk profile than their weight alone would suggest.
A later study demonstrated that Tesamorelin improves both the quantity and the density of visceral and subcutaneous adipose tissue in people with HIV, indicating that the metabolic quality of fat tissue changes alongside its volume. Separately, Tesamorelin significantly reduced liver fat fraction compared to placebo in HIV-infected patients with abdominal fat accumulation, supporting a hepatic metabolic benefit that extends beyond simply reducing visceral fat volume.
This evidence base, built on CT-measured endpoints and published phase 3 data, is substantially more robust than what exists for any other GHRH analogue.
Investigational Use in Patients Without HIV
The FDA approval is for HIV-associated lipodystrophy. Physicians may also prescribe Tesamorelin off-label for visceral fat reduction and metabolic support in patients without HIV. This is standard medical practice: approved medicines are routinely used outside their licensed indication when the clinical evidence and the patient’s situation support it.
Off-label use in patients without HIV is supported by the mechanistic evidence (GHRH agonism drives visceral fat reduction through the same pathway regardless of HIV status), the visceral fat biology described above, and the available clinical data from the HIV trial population. It is investigational rather than approved, which means there is no dedicated phase 3 trial in a non-HIV population. Patients considering off-label use should understand this distinction and be managed under physician supervision with appropriate monitoring.
Patients who may be appropriate candidates for investigational use include adults with significant visceral adiposity who have not responded adequately to lifestyle modification, patients with metabolic syndrome characterised by central adiposity and elevated triglycerides, and individuals who are not candidates for GLP-1 class agents and need an alternative approach targeting visceral fat specifically.
Tesamorelin vs CJC-1295 and Ipamorelin: A Practical Comparison
All three peptides increase growth hormone output, but through different mechanisms and with very different evidence bases.
Tesamorelin acts on pituitary GHRH receptors with a short half-life (minutes), administered daily to produce a single physiological GH pulse, typically in the evening. It has phase 3 trial data specifically demonstrating visceral fat reduction and is the preferred choice when visceral fat reduction is the primary clinical goal.
CJC-1295 is also a GHRH analogue, but the DAC (Drug Affinity Complex) modification extends its half-life to several days. This produces more sustained baseline GH elevation rather than a distinct daily pulse. CJC-1295 has no approved indication in any country and no phase 3 trial programme. It is used for broader GH axis augmentation, including body composition, recovery, and sleep quality support.
Ipamorelin acts on ghrelin receptors rather than GHRH receptors, stimulating GH secretion through a complementary and distinct pathway. It is not a GHRH analogue and does not directly overlap with Tesamorelin. It is commonly combined with CJC-1295 to amplify GH release through dual-pathway stimulation. See our guide on Ipamorelin and CJC-1295 in Thailand for more on how that combination is used clinically. Tesamorelin is not typically combined with Ipamorelin in the same way because the FDA-approved protocol is a standalone daily injection and the additional benefit of dual-pathway stimulation over Tesamorelin alone has not been studied.
The regulatory distinction matters: Tesamorelin has a completed phase 3 programme and an approved indication. CJC-1295 and Ipamorelin are investigational in all countries. A physician selecting between these agents will weigh the patient’s primary clinical goal, their glucose and metabolic status, and which mechanism is most appropriate for their situation.
Monitoring Requirements
Tesamorelin is among the better-monitored peptides in clinical practice because IGF-1 provides a direct, quantifiable biomarker of pharmacological activity. Baseline IGF-1 is required before starting the protocol. A follow-up IGF-1 measurement at 4 to 8 weeks confirms the dose is producing the intended response and that IGF-1 has not risen above the age-adjusted upper limit of normal.
Fasting glucose and HbA1c should be measured at baseline because Tesamorelin can modestly affect glucose handling. Patients with pre-diabetes or diabetes require closer glucose monitoring throughout the protocol. Physical measurements (waist circumference, body weight) and a clinical review at 12 weeks allow the physician to assess initial response and determine whether to continue, adjust, or discontinue.
The phase 3 trials ran to 26 weeks as the primary endpoint window, and visceral fat reduction was statistically significant by week 8 in CT measurements. Effects are reversible on discontinuation, with visceral fat tending to return toward baseline over months after stopping. Some patients choose a lower-dose maintenance protocol under physician supervision after an initial treatment cycle.
Start with a full metabolic assessment.
Your physician reviews your baseline labs before recommending any protocol. No guesswork, no generic dosing schedules.
Accessing Tesamorelin in Thailand
Tesamorelin is available at Peptides Thailand through a physician-supervised protocol that includes a clinical assessment, baseline bloodwork, structured monitoring, and cold-chain delivery of clinical-grade, COA-verified preparations.
The physician assessment covers IGF-1 baseline, fasting glucose, HbA1c, lipid panel, and a review of any history of cancer, pituitary disease, or other contraindications. Every batch of Tesamorelin dispensed through this clinic is accompanied by a Certificate of Analysis confirming purity and concentration. Self-sourcing or self-dosing without physician oversight is not supported: the IGF-1 monitoring requirement cannot be managed responsibly without access to blood testing and clinical review.
Video consultations are available nationwide in Thailand, with physician-prescribed protocols and cold-chain delivery to Bangkok, Phuket, Chiang Mai, Koh Samui, Pattaya, Hua Hin, Chiang Rai, and all other regions. International patients visiting Thailand for medical care are also supported.
Book a consultation to discuss whether Tesamorelin is appropriate for your clinical situation.
A Note on Evidence Standards
Tesamorelin is the most evidence-supported peptide on this site because it has completed a regulatory process that requires phase 3 data, adverse event documentation, and manufacturing standards. That stronger evidence base is a legitimate factor in clinical decision-making, but it does not eliminate the need for physician oversight, individualised dosing, and IGF-1 monitoring. The requirements for safe and responsible use apply regardless of the evidence tier.
For patients comparing Tesamorelin to other visceral fat or metabolic support options, including GLP-1 class agents, the Tesamorelin peptide page covers candidacy criteria, protocol design, contraindications, and how the GH-axis mechanism differs from appetite and satiety-based approaches. For a practical guide to Tesamorelin access and protocols in Thailand, see Tesamorelin Peptide in Thailand.
